Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer (Q41388354)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 1997

Language	Label	Description	Also known as
English	Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer	scientific article published on March 1997

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1 reference

Europe PubMed Central

Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Coukell AJ

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Faulds D

2

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

publication date

1 March 1997

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

453-482

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

https://scigraph.springernature.com/pub.10.2165/00003495-199753030-00008

0 references

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose optimization of anthracyclines

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of biotransformation in anthracycline-induced cardiotoxicity in mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant therapy for early stage breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Conventional versus high-dose epidoxorubicin as single agent in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A daily diary for quality of life measurement in advanced breast cancer trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin + G-CSF as peripheral blood progenitor cells (PBPC) mobilising agents in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme activities and level of SH groups in breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer. A review

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of drug resistance is reduced with idarubicin relative to other anthracyclines

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comprehensive management of locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin. Clinical pharmacology and dose-effect relationship

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced breast cancer: a current perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of epirubicin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-intensive chemotherapy with cytokine support.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unproven breast-cancer therapy widely used in USA

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy-related leukemia associated with high-dose 4-epi-doxorubicin and cyclophosphamide used as adjuvant chemotherapy for breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In-vivo and in-vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversal of multidrug resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-intensified treatment of breast cancer: current results

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity and safety of epirubicin plus paclitaxel in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro digital cell image analysis of morphonuclear modifications induced by natural DNA-interacting anticancer drugs in three neoplastic cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and toxicity of two schedules of high dose epirubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin and the risk of leukemia: not substantiated? International Collaborative Cancer Group Steering Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary chemotherapy for resectable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of new anthracycline analogues in combination with interferon alfa

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meeting highlights: international consensus panel on the treatment of primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anthracycline resistance in breast cancer: clinical applications of current knowledge

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Breast cancer studies in The Netherlands

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of response to therapy in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II feasibility study of high dose epirubicin-based regimens for untreated patients with small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of verapamil on the pharmacokinetics and metabolism of epirubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drugs ten years later: epirubicin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: a randomised study in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized cooperative study of perioperative chemotherapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Present and future projects of the International Breast Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative chemotherapy in operable breast cancer. The influence of timing FEC in relation to surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lean body mass, body surface area and epirubicin kinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of primary chemotherapy in early breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9074845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199753030-00008

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41388354&oldid=2144162216"